Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 2, 2009, Pages 108-124

  Dome, Balazs ^a   Timar, Jozsef ^b   Ladanyi, Andrea ^b   Paku, Sandor ^c   Renyi Vamos, Ferenc ^a   Klepetko, Walter ^d   Lang, Gyorgy ^d   Dome, Peter ^c   Bogos, Krisztina ^a   Tovari, Jozsef ^a,b  

^a NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; Cancer; Circulating endothelial cells; Endothelial progenitor cells; Proangiogenic hematopoietic cells; Vasculogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; ENZASTAURIN; ETOPOSIDE; GANCICLOVIR; GEMCITABINE; INTERLEUKIN 2; LENTIVIRUS VECTOR; RECOMBINANT ERYTHROPOIETIN; RETROVIRUS VECTOR; SUNITINIB; THALIDOMIDE; THYMIDINE KINASE; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER GENE THERAPY; CANCER GROWTH; CANCER MODEL; CANCER THERAPY; CARCINOGENESIS; CELL POPULATION; CELL TYPE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; CYTOLOGY; DISEASE MARKER; ENDOTHELIUM; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEMATOPOIETIC STEM CELL; HUMAN; KIDNEY CANCER; LIVER CANCER; LOW DRUG DOSE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; REGULATORY MECHANISM; REVIEW; STOMACH CANCER; TUMOR VASCULARIZATION;

ANIMALS; BONE MARROW; CYTOKINES; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELLS;

EID: 58149151390     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.06.009     Document Type: Review

References (155)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
2. Asahara T., and Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 287 (2004) C572-C579
3. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
4. Dome B., Hendrix M.J., Paku S., Tovari J., and Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 170 (2007) 1-15
5. Brigati C., Noonan D.M., Albini A., and Benelli R. Tumors and inflammatory infiltrates: friends or foes?. Clin Exp Metastasis 19 (2002) 247-258
6. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
7. De Palma M., and Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 1766 (2006) 159-166
8. Schmid M.C., and Varner J.A. Myeloid cell trafficking and tumor angiogenesis. Cancer Lett 250 (2007) 1-8
9. Blann A.D., Woywodt A., Bertolini F., et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 93 (2005) 228-235
10. Hladovec J. Circulating endothelial cells as a sign of vessel wall lesions. Physiol Bohemoslov 27 (1978) 140-144
11. Wright H.P., and Glacometti N.J. Circulating endothelial cells and arterial endothelial mitosis in anaphylactic shock. Br J Exp Pathol 53 (1972) 1-4
12. Sbarbati R., de Boer M., Marzilli M., Scarlattini M., Rossi G., and van Mourik J.A. Immunologic detection of endothelial cells in human whole blood. Blood 77 (1991) 764-769
13. George F., Brisson C., Poncelet P., et al. Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 67 (1992) 147-153
14. Bardin N., George F., Mutin M., et al. S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens 48 (1996) 531-539
15. George F., Brouqui P., Boffa M.C., et al. Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever. Blood 82 (1993) 2109-2116
16. Khan S.S., Solomon M.A., and McCoy Jr. J.P. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 64 (2005) 1-8
17. Goon P.K., Boos C.J., Stonelake P.S., and Lip G.Y. Circulating endothelial cells in malignant disease. Future Oncol 1 (2005) 813-820
18. Woywodt A., Goldberg C., Scheer J., Regelsberger H., Haller H., and Haubitz M. An improved assay for enumeration of circulating endothelial cells. Ann Hematol 83 (2004) 491-494
19. Duda D.G., Cohen K.S., Scadden D.T., and Jain R.K. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2 (2007) 805-810
20. Strijbos M.H., Kraan J., den Bakker M.A., Lambrecht B.N., Sleijfer S., and Gratama J.W. Cells meeting our immunophenotypic criteria of endothelial cells are large platelets. Cytometry B Clin Cytom 72 (2007) 86-93
21. Mancuso P., Burlini A., Pruneri G., Goldhirsch A., Martinelli G., and Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97 (2001) 3658-3661
22. Beerepoot L.V., Mehra N., Vermaat J.S., Zonnenberg B.A., Gebbink M.F., and Voest E.E. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15 (2004) 139-145
23. Zhang H., Vakil V., Braunstein M., et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105 (2005) 3286-3294
24. Wierzbowska A., Robak T., Krawczynska A., et al. Circulating endothelial cells in patients with acute myeloid leukemia. Eur J Haematol 75 (2005) 492-497
25. Furstenberger G., von Moos R., Lucas R., et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94 (2006) 524-531
26. Rowand J.L., Martin G., Doyle G.V., et al. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71 (2007) 105-113
27. Norden-Zfoni A., Desai J., Manola J., et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13 (2007) 2643-2650
28. Della Porta M.G., Malcovati L., Rigolin G.M., et al. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. Leukemia December (2007) [Epub ahead of print]
29. Go R.S., Jobe D.A., Asp K.E., et al. Circulating endothelial cells in patients with chronic lymphocytic leukemia. Ann Hematol January (2008) [Epub ahead of print]
30. Burger P.E., Coetzee S., McKeehan W.L., et al. Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells. Blood 100 (2002) 3527-3535
31. Massa M., Rosti V., Ferrario M., et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105 (2005) 199-206
32. Heissig B., Werb Z., Rafii S., and Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost 90 (2003) 570-576
33. Hristov M., Erl W., and Weber P.C. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 23 (2003) 1185-1189
34. Rafii S., Lyden D., Benezra R., Hattori K., and Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer 2 (2002) 826-835
35. Wognum A.W., Eaves A.C., and Thomas T.E. Identification and isolation of hematopoietic stem cells. Arch Med Res 34 (2003) 461-475
36. Peichev M., Naiyer A.J., Pereira D., et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95 (2000) 952-958
37. Kalka C., Masuda H., Takahashi T., et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 86 (2000) 1198-1202
38. Prater D.N., Case J., Ingram D.A., and Yoder M.C. Working hypothesis to redefine endothelial progenitor cells. Leukemia 21 (2007) 1141-1149
39. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
40. Dimmeler S., and Zeiher A.M. Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res 87 (2000) 434-439
41. Kalka C., Masuda H., Takahashi T., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97 (2000) 3422-3427
42. Yoon C.H., Hur J., Park K.W., et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 112 (2005) 1618-1627
43. Khakoo A.Y., and Finkel T. Endothelial progenitor cells. Annu Rev Med 56 (2005) 79-101
44. Rafii S., Heissig B., and Hattori K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 9 (2002) 631-641
45. Asahara T., Takahashi T., Masuda H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18 (1999) 3964-3972
46. Ho J.W., Pang R.W., Lau C., et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44 (2006) 836-843
47. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5 (1999) 434-438
48. Natori T., Sata M., Washida M., Hirata Y., Nagai R., and Makuuchi M. G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 297 (2002) 1058-1061
49. Bahlmann F.H., De Groot K., Spandau J.M., et al. Erythropoietin regulates endothelial progenitor cells. Blood 103 (2004) 921-926
50. Heeschen C., Aicher A., Lehmann R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (2003) 1340-1346
51. Aicher A., Zeiher A.M., and Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 45 (2005) 321-325
52. Sinclair A.M., Todd M.D., Forsythe K., Knox S.J., Elliott S., and Begley C.G. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110 (2007) 477-488
53. Lövey J., Bereczky B., Gilly R., et al. Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels. Strahlenther Onkol 184 (2008) 1-7
54. Tóvári J., Gilly R., Rásó E., et al. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res 65 (2005) 7186-7193
55. Li B., Sharpe E.E., Maupin A.B., et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20 (2006) 1495-1497
56. Moore M.A., Hattori K., Heissig B., et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 938 (2001) 36-47
57. Li X., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest 115 (2005) 118-127
58. Hattori K., Dias S., Heissig B., et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193 (2001) 1005-1014
59. Aicher A., Heeschen C., Mildner-Rihm C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9 (2003) 1370-1376
60. Llevadot J., Murasawa S., Kureishi Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108 (2001) 399-405
61. Strehlow K., Werner N., Berweiler J., et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107 (2003) 3059-3065
62. Laufs U., Werner N., Link A., et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109 (2004) 220-226
63. Seeger F.H., Haendeler J., Walter D.H., et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 111 (2005) 1184-1191
64. Verma S., Kuliszewski M.A., Li S.H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
65. Lyden D., Hattori K., Dias S., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7 (2001) 1194-1201
66. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
67. Goon P.K., Lip G.Y., Boos C.J., Stonelake P.S., and Blann A.D. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8 (2006) 79-88
68. De Palma M., Venneri M.A., Roca C., and Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9 (2003) 789-795
69. Gothert J.R., Gustin S.E., van Eekelen J.A., et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 104 (2004) 1769-1777
70. Spring H., Schuler T., Arnold B., Hammerling G.J., and Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA 102 (2005) 18111-18116
71. Ruzinova M.B., Schoer R.A., Gerald W., et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4 (2003) 277-289
72. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
73. Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63 (2003) 4342-4346
74. Urbich C., Aicher A., Heeschen C., et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 39 (2005) 733-742
75. Gao D., Nolan D.J., Mellick A.S., Bambino K., McDonnell K., and Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319 (2008) 195-198
76. Peters B.A., Diaz L.A., Polyak K., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11 (2005) 261-262
77. Igreja C., Courinha M., Cachaco A.S., et al. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. Haematologica 92 (2007) 469-477
78. Hilbe W., Dirnhofer S., Oberwasserlechner F., et al. CD133 positive endothelial progenitor cells contribute to the tumor vasculature in non-small cell lung cancer. J Clin Pathol 57 (2004) 965-969
79. Yu D., Sun X., Qiu Y., et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res 13 (2007) 3814-3824
80. Dome B., Timar J., Dobos J., et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66 (2006) 7341-7347
81. Mehra N., Penning M., Maas J., et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 12 (2006) 4859-4866
82. Lin E.H., Hassan M., Li Y., et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110 (2007) 534-542
83. Pircher A., Kähler C.M., Skvortsov S., et al. Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance. Oncol Rep 19 (2008) 345-352
84. Richter-Ehrenstein C., Rentzsch J., Runkel S., Schneider A., and Schönfelder G. Endothelial progenitor cells in breast cancer patients. Breast Cancer Res Treat 106 (2007) 343-349
85. Naik R.P., Jin D., Chuang E., et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 107 (2008) 133-138
86. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
87. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23 (2005) 8136-8139
88. Massa M., Rosti V., Ramajoli I., et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 23 (2005) 5688-5695
89. Zheng P.P., Hop W.C., Luider T.M., Sillevis Smitt P.A., and Kros J.M. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol 62 (2007) 40-48
90. Takakura N. Role of hematopoietic lineage cells as accessory components in blood vessel formation. Cancer Sci 97 (2006) 568-574
91. Moore M.A., and Metcalf D. Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo. Br J Haematol 18 (1970) 279-296
92. Dieterlen-Lièvre F., and Martin C. Diffuse intraembryonic hemopoiesis in normal and chimeric avian development. Dev Biol 88 (1981) 180-191
93. Lu L.S., Wang S.J., and Auerbach R. In vitro and in vivo differentiation into B cells, T cells, and myeloid cells of primitive yolk sac hematopoietic precursor cells expanded >100-fold by coculture with a clonal yolk sac endothelial cell line. Proc Natl Acad Sci USA 93 (1996) 14782-14787
94. Prindull G. Hemangioblasts representing a functional endothelio-hematopoietic entity in ontogeny, postnatal life, and CML neovasculogenesis. Stem Cell Rev 1 (2005) 277-284
95. Forrai A., and Robb L. The hemangioblast-between blood and vessels. Cell Cycle 2 (2003) 86-90
96. Nienartowicz A., Sobaniec-Lotowska M.E., Jarocka-Cyrta E., and Lemancewicz D. Mast cells in neoangiogenesis. Med Sci Monit 12 (2006) RA53-RA56
97. Zhang W., Stoica G., Tasca S.I., Kelly K.A., and Meininger C.J. Modulation of tumor angiogenesis by stem cell factor. Cancer Res 60 (2000) 6757-6762
98. Coussens L.M., Raymond W.W., Bergers G., et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13 (1999) 1382-1397
99. Sica A., Schioppa T., Mantovani A., and Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42 (2006) 717-727
100. Sica A., and Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117 (2007) 1155-1166
101. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., and Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56 (1996) 4625-4629
102. Takanami I., Takeuchi K., and Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 57 (1999) 138-142
103. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., and Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80 (2006) 1183-1196
104. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 (2005) 263-274
105. Serafini P., Borrello I., and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16 (2006) 53-65
106. Yang L., DeBusk L.M., Fukuda K., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 (2004) 409-421
107. Pak A.S., Wright M.A., Matthews J.P., Collins S.L., Petruzzelli G.J., and Young M.R. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1 (1995) 95-103
108. Almand B., Clark J.I., Nikitina E., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166 (2001) 678-689
109. Ochoa A.C., Zea A.H., Hernandez C., and Rodriguez P.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13 2 Pt 2 (2007) 721s-726s
110. De Palma M., Venneri M.A., Galli R., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8 (2005) 211-226
111. Venneri M.A., De Palma M., Ponzoni M., et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109 (2007) 5276-5285
112. Inoshima N., Nakanishi Y., Minami T., et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 8 (2002) 3480-3486
113. Ishigami S., Natsugoe S., Matsumoto M., et al. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 10 (2003) 1237-1240
114. Ladanyi A., Kiss J., Somlai B., et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56 (2007) 1459-1469
115. Lutz M.B., and Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol 23 (2002) 445-449
116. Gabrilovich D.I., Chen H.L., Girgis K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996) 1096-1103
117. Geissmann F., Revy P., Regnault A., et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 162 (1999) 4567-4575
118. Saito H., Tsujitani S., Ikeguchi M., Maeta M., and Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 78 (1998) 1573-1577
119. Sozzani S., Rusnati M., Riboldi E., Mitola S., and Presta M. Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 28 (2007) 385-392
120. Conejo-Garcia J.R., Benencia F., Courreges M.C., et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10 (2004) 950-958
121. Conejo-Garcia J.R., Buckanovich R.J., Benencia F., et al. Vascular leukocytes contribute to tumor vascularization. Blood 105 (2005) 679-681
122. Udagawa T., Puder M., Wood M., Schaefer B.C., and D'Amato R.J. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J 20 (2006) 95-102
123. Grunewald M., Avraham I., Dor Y., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124 (2006) 175-189
124. Kaplan R.N., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
125. Harraz M., Jiao C., Hanlon H.D., Hartley R.S., and Schatteman G.C. CD34- blood-derived human endothelial cell progenitors. Stem Cells 19 (2001) 304-312
126. Rehman J., Li J., Orschell C.M., and March K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107 (2003) 1164-1169
127. Yoder M.C., Mead L.E., Prater D., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109 (2007) 1801-1809
128. Qin Z., Schwartzkopff J., Pradera F., et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63 (2003) 4095-4100
129. Freeman M.R., Schneck F.X., Gagnon M.L., et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55 (1995) 4140-4145
130. Kiss J., Tímár J., Somlai B., et al. Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma. Pathol Oncol Res 13 (2007) 21-31
131. Yao L., Sgadari C., Furuke K., Bloom E.T., Teruya-Feldstein J., and Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93 (1999) 1612-1621
132. de Visser K.E., Korets L.V., and Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7 (2005) 411-423
133. Ferrari N., Glod J., Lee J., Kobiler D., and Fine H.A. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Ther 10 (2003) 647-656
134. Davidoff A.M., Ng C.Y., Brown P., et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 7 (2001) 2870-2879
135. Wei J., Blum S., Unger M., et al. Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 5 (2004) 477-488
136. Ojeifo J.O., Lee H.R., Rezza P., Su N., and Zwiebel J.A. Endothelial cell-based systemic gene therapy of metastatic melanoma. Cancer Gene Ther 8 (2001) 636-648
137. Rancourt C., Robertson III M.W., Wang M., et al. Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary. Clin Cancer Res 4 (1998) 265-270
138. Provenzale J.M. Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR Am J Roentgenol 188 (2007) 11-23
139. DePrimo S.E., and Bello C. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol 18 Suppl. 10 (2007) x11-x19
140. Rüegg C., Meuwly J.Y., Driscoll R., Werffeli P., Zaman K., and Stupp R. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med 3 (2003) 673-691
141. Drevs J., Zirrgiebel U., Schmidt-Gersbach C.I., et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16 (2005) 558-565
142. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
143. Santimaria M., Moscatelli G., Viale G.L., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9 (2003) 571-579
144. Beer A.J., Grosu A.L., Carlsen J., et al. [18F]Galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13 22 Pt 1 (2007) 6610-6616
145. Bertolini F., Shaked Y., Mancuso P., and Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6 (2006) 835-845
146. Shaked Y., Ciarrocchi A., Franco M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006) 1785-1787
147. Schuch G., Heymach J.V., Nomi M., et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63 (2003) 8345-8350
148. Capillo M., Mancuso P., Gobbi A., et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9 (2003) 377-382
149. Shaked Y., Bertolini F., Man S., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 (2005) 101-111
150. Dignat-George F., Sabatier F., Blann A., and Woywodt A. Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay?. J Clin Oncol 25 (2007) e1-2
151. Duda D.G., Cohen K.S., di Tomaso E., et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24 (2006) 1449-1453
152. Buckstein R., Kerbel R.S., Shaked Y., et al. High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 12 (2006) 5190-5198
153. Bender J.L., Adamson P.C., Reid J.M., et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 26 (2008) 399-405
154. Twardowski P.W., Smith-Powell L., Carroll M., et al. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest 26 (2008) 53-59
155. Kim H.K., Song K.S., Kim H.O., et al. Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer. Cancer Lett 198 (2003) 83-88